IL229226A0 - Pirfenidone and anti-fibrotic treatment in selected patients - Google Patents
Pirfenidone and anti-fibrotic treatment in selected patientsInfo
- Publication number
- IL229226A0 IL229226A0 IL229226A IL22922613A IL229226A0 IL 229226 A0 IL229226 A0 IL 229226A0 IL 229226 A IL229226 A IL 229226A IL 22922613 A IL22922613 A IL 22922613A IL 229226 A0 IL229226 A0 IL 229226A0
- Authority
- IL
- Israel
- Prior art keywords
- pirfenidone
- selected patients
- fibrotic therapy
- fibrotic
- therapy
- Prior art date
Links
- 230000003510 anti-fibrotic effect Effects 0.000 title 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title 1
- 229960003073 pirfenidone Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489936P | 2011-05-25 | 2011-05-25 | |
| US201161490057P | 2011-05-26 | 2011-05-26 | |
| US201161523047P | 2011-08-12 | 2011-08-12 | |
| US201161524961P | 2011-08-18 | 2011-08-18 | |
| PCT/US2012/039538 WO2012162592A1 (en) | 2011-05-25 | 2012-05-25 | Pirfenidone and anti-fibrotic therapy in selected patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL229226A0 true IL229226A0 (en) | 2014-01-30 |
Family
ID=47217770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL229226A IL229226A0 (en) | 2011-05-25 | 2013-11-04 | Pirfenidone and anti-fibrotic treatment in selected patients |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150164874A1 (https=) |
| EP (1) | EP2713732A4 (https=) |
| JP (1) | JP6170040B2 (https=) |
| KR (1) | KR20140022048A (https=) |
| AU (1) | AU2012258575B2 (https=) |
| CA (1) | CA2835438A1 (https=) |
| HK (1) | HK1197159A1 (https=) |
| IL (1) | IL229226A0 (https=) |
| MX (1) | MX2013013752A (https=) |
| SG (1) | SG195110A1 (https=) |
| WO (1) | WO2012162592A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008157786A1 (en) | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| JP2014507474A (ja) * | 2011-03-08 | 2014-03-27 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ｎ−アリールピリジノン |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| EP3782604A1 (en) * | 2013-07-31 | 2021-02-24 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| EP3194446B1 (en) * | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| ES2764840T3 (es) * | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| US20180064662A1 (en) * | 2015-03-05 | 2018-03-08 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| WO2018167103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| AU2018322475A1 (en) * | 2017-08-22 | 2020-03-05 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| EP3969033A4 (en) * | 2019-05-17 | 2023-06-14 | The Regents of the University of California | MPS-MODIFIED PEPTIDES AND THEIR USE |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| EP3821946A1 (en) * | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| CA3171622A1 (en) * | 2020-03-13 | 2021-09-16 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| CN114617890A (zh) * | 2020-12-08 | 2022-06-14 | 四川夏派森医药科技有限公司 | DH404在治疗SARS-CoV-2感染中的应用 |
| CN112640887B (zh) * | 2020-12-25 | 2022-05-13 | 武汉睿健医药科技有限公司 | 一种神经干细胞冻存液及其应用 |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| CN114097807B (zh) * | 2021-11-25 | 2023-05-05 | 兰州大学 | 巴多索隆类化合物在抗农业病原真菌中的用途 |
| JP2025511066A (ja) * | 2022-03-31 | 2025-04-15 | ピュアテック・エル・ワイ・ティ・１００・インコーポレイテッド | デューピルフェニドンにより間質性肺疾患ならびに他の線維化介在性肺疾患及び障害を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1258484E (pt) * | 2000-02-18 | 2009-04-03 | Kyowa Hakko Kirin Co Ltd | Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos |
| JP2005531628A (ja) * | 2002-06-28 | 2005-10-20 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 肺線維症の処置のための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ）フェニル］−ベンズアミド |
| WO2004103296A2 (en) * | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005110478A2 (en) * | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| SG174050A1 (en) * | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| JP2010502224A (ja) * | 2006-09-08 | 2010-01-28 | アボット・ラボラトリーズ | インターロイキン１３結合タンパク質 |
| WO2008157786A1 (en) * | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| AP2011005824A0 (en) * | 2009-01-26 | 2011-08-31 | Intermune Inc | Methods for treating acute myocardial infarctions and associated disorders. |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
-
2012
- 2012-05-25 CA CA2835438A patent/CA2835438A1/en not_active Abandoned
- 2012-05-25 KR KR1020137028921A patent/KR20140022048A/ko not_active Ceased
- 2012-05-25 EP EP12788732.1A patent/EP2713732A4/en not_active Withdrawn
- 2012-05-25 US US14/373,276 patent/US20150164874A1/en not_active Abandoned
- 2012-05-25 WO PCT/US2012/039538 patent/WO2012162592A1/en not_active Ceased
- 2012-05-25 AU AU2012258575A patent/AU2012258575B2/en not_active Ceased
- 2012-05-25 HK HK14109929.1A patent/HK1197159A1/xx unknown
- 2012-05-25 MX MX2013013752A patent/MX2013013752A/es not_active Application Discontinuation
- 2012-05-25 SG SG2013086541A patent/SG195110A1/en unknown
- 2012-05-25 JP JP2014512134A patent/JP6170040B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-04 IL IL229226A patent/IL229226A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014518880A (ja) | 2014-08-07 |
| AU2012258575A1 (en) | 2013-11-21 |
| WO2012162592A1 (en) | 2012-11-29 |
| MX2013013752A (es) | 2014-08-01 |
| JP6170040B2 (ja) | 2017-07-26 |
| NZ617415A (en) | 2017-07-28 |
| AU2012258575B2 (en) | 2017-03-02 |
| EP2713732A1 (en) | 2014-04-09 |
| CA2835438A1 (en) | 2012-11-29 |
| US20150164874A1 (en) | 2015-06-18 |
| EP2713732A4 (en) | 2014-12-03 |
| SG195110A1 (en) | 2013-12-30 |
| HK1197159A1 (en) | 2015-01-09 |
| KR20140022048A (ko) | 2014-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL229226A0 (en) | Pirfenidone and anti-fibrotic treatment in selected patients | |
| AP2013007178A0 (en) | BCMA-based stratification and therapy for multiplemyeloma patients | |
| EP2788075A4 (en) | DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT | |
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| IL231386A0 (en) | Pyrazoloquinolinone derivatives, their preparation and medical use | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| ZA201403372B (en) | Therapeutic agents and uses thereof | |
| GB201218084D0 (en) | Novel compounds and methods for use in medicine | |
| EP2896294A4 (en) | MICRORNA IN HUMAN MILK AND USE THEREOF | |
| EP2934632B8 (en) | Device and method for inhibiting movement of a medical device in a patient | |
| SI2729469T1 (sl) | Derivati orvinola in tevinola uporabni pri zdravljenju zlorabe mamil in alkohola | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| GB2499241B (en) | Patient transport chair and track arrangement | |
| SG11201501604TA (en) | Pyridinone compounds for use in photodynamic therapy | |
| PT2931716T (pt) | Derivados de piridona e suas utilizações no tratamento da tuberculose | |
| EP2706962A4 (en) | SURFACE CHARACTERISTICS OF DRUG RETENTION IN AN IMPLANTABLE MEDICAL DEVICE | |
| ZA201403477B (en) | Apricitabine and pi combination therapy | |
| GB201112260D0 (en) | Medical device and related methods | |
| GB201102222D0 (en) | Inventions and therapy | |
| GB201102221D0 (en) | Inventions and therapy | |
| GB201102238D0 (en) | Inventions and therapy | |
| GB201102208D0 (en) | Inventions and therapy | |
| GB201102236D0 (en) | Inventions and therapy | |
| GB201102234D0 (en) | Inventions and therapy | |
| GB201102232D0 (en) | Inventions and therapy |